Abstract
Tuberculosis (TB) is the most common opportunistic infection and the leading cause of death in patients with human immunodeficiency virus (HIV) worldwide. Persons with advanced HIV infection and those not on antiretroviral therapy (ART) are at highest risks of morbidity and mortality. Thus, early diagnosis and treatment of both HIV and TB are keys to treatment success. Concurrent treatment of both infections can be challenging due to high pill burden, overlapping toxicities, drug interactions, adherence concerns, and the potential of immune reconstitution inflammatory syndrome. This chapter provides an overview of treatment regimens and duration of therapy for drug-susceptible TB, management of adverse drug reactions, monitoring parameters, adherence interventions, and appropriate timing for ART initiation in this patient population.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
WHO. Global Tuberculosis Report - 2017. 2017 January 1, 2018]; Available from: http://www.who.int/tb/publications/global_report/en/
Bisson GP, Zetola N, Collman RG (2015) Persistent high mortality in advanced HIV/TB despite appropriate antiretroviral and antitubercular therapy: an emerging challenge. Curr HIV/AIDS Rep 12(1):107–116
Nahid P et al (2016) Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. Clin Infect Dis 63(7):e147–e195
WHO. Guidelines for treatment of drug-susceptible tuberculosis and patient care (2017 update). 2017 January 1, 2018; Available from: http://www.who.int/tb/publications/2017/dstb_guidance_2017/en/
Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents:recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. 2017 December 10, 2017 January 1, 2018]; Available from: http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf
WHO. Improving the diagnosis and treatment smear-negative pulmonary and extrapulmonary tuberculosis among adults and adolescents. Recommendations for HIV-prevalent and resource-constrained settings. . 2007 January 1, 2018; Available from: http://whqlibdoc.who.int/hq/2007/WHO_HTM_TB_2007.379_eng.pdf
Padmapriyadarsini C et al (2013) Evaluation of a diagnostic algorithm for sputum smear-negative pulmonary tuberculosis in HIV-infected adults. J Acquir Immune Defic Syndr 63(3):331–338
Wilson D et al (2011) Evaluation of the World Health Organization algorithm for the diagnosis of HIV-associated sputum smear-negative tuberculosis. Int J Tuberc Lung Dis 15(7):919–924
Griesel R et al (2017) Optimizing tuberculosis diagnosis in HIV-infected inpatients meeting the criteria of seriously ill in the WHO algorithm. Clin Infect Dis
Mitnick CD, McGee B, Peloquin CA (2009) Tuberculosis pharmacotherapy: strategies to optimize patient care. Expert Opin Pharmacother 10(3):381–401
Khan FA et al (2010) Treatment of active tuberculosis in HIV-coinfected patients: a systematic review and meta-analysis. Clin Infect Dis 50(9):1288–1299
Swaminathan S et al (2010) Efficacy of a 6-month versus 9-month intermittent treatment regimen in HIV-infected patients with tuberculosis: a randomized clinical trial. Am J Respir Crit Care Med 181(7):743–751
Perriens JH et al (1995) Pulmonary tuberculosis in HIV-infected patients in Zaire. A controlled trial of treatment for either 6 or 12 months. N Engl J Med 332(12):779–784
Li J et al (2005) Relapse and acquired rifampin resistance in HIV-infected patients with tuberculosis treated with rifampin- or rifabutin-based regimens in New York City, 1997–2000. Clin Infect Dis 41(1):83–91
Nettles RE et al (2004) Risk factors for relapse and acquired rifamycin resistance after directly observed tuberculosis treatment: a comparison by HIV serostatus and rifamycin use. Clin Infect Dis 38(5):731–736
Vashishtha R et al (2013) Efficacy and safety of thrice weekly DOTS in tuberculosis patients with and without HIV co-infection: an observational study. BMC Infect Dis 13:468
Burman W et al (2006) Acquired rifamycin resistance with twice-weekly treatment of HIV-related tuberculosis. Am J Respir Crit Care Med 173(3):350–356
Jo KW et al (2014) Risk factors for 1-year relapse of pulmonary tuberculosis treated with a 6-month daily regimen. Respir Med 108(4):654–659
Horne DJ et al (2010) Sputum monitoring during tuberculosis treatment for predicting outcome: systematic review and meta-analysis. Lancet Infect Dis 10(6):387–394
Perwitasari DA, Atthobari J, Wilffert B (2015) Pharmacogenetics of isoniazid-induced hepatotoxicity. Drug Metab Rev 47(2):222–228
Ohno M et al (2000) Slow N-acetyltransferase 2 genotype affects the incidence of isoniazid and rifampicin-induced hepatotoxicity. Int J Tuberc Lung Dis 4(3):256–261
Huang YS et al (2002) Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis. Hepatology 35(4):883–889
Pasipanodya JG, Srivastava S, Gumbo T (2012) Meta-analysis of clinical studies supports the pharmacokinetic variability hypothesis for acquired drug resistance and failure of antituberculosis therapy. Clin Infect Dis 55(2):169–177
Chien JY et al (2014) Safety of rifabutin replacing rifampicin in the treatment of tuberculosis: a single-centre retrospective cohort study. J Antimicrob Chemother 69(3):790–796
Vernon A et al (1999) Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Tuberculosis Trials Consortium. Lancet 353(9167):1843–1847
Savic RM et al (2017) Defining the optimal dose of rifapentine for pulmonary tuberculosis: exposure-response relations from two phase II clinical trials. Clin Pharmacol Ther 102(2):321–331
Dorman SE et al (2015) Daily rifapentine for treatment of pulmonary tuberculosis. A randomized, dose-ranging trial. Am J Respir Crit Care Med 191(3):333–343
Boeree MJ et al (2017) High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial. Lancet Infect Dis 17(1):39–49
Steingart KR et al (2011) Higher-dose rifampin for the treatment of pulmonary tuberculosis: a systematic review. Int J Tuberc Lung Dis 15(3):305–316
Velasquez GE et al (2018) Efficacy and safety of high-dose rifampin in pulmonary tuberculosis. A randomized controlled trial. Am J Respir Crit Care Med 198(5):657–666
Schimkat M et al (1996) Rifabutin-associated anterior uveitis in patients infected with human immunodeficiency virus. Ger J Ophthalmol 5(4):195–201
Jacobs DS et al (1994) Acute uveitis associated with rifabutin use in patients with human immunodeficiency virus infection. Am J Ophthalmol 118(6):716–722
Baciewicz AM et al (2013) Update on rifampin, rifabutin, and rifapentine drug interactions. Curr Med Res Opin 29(1):1–12
Cremades R et al (2011) Comparison of the bactericidal activity of various fluoroquinolones against Mycobacterium tuberculosis in an in vitro experimental model. J Antimicrob Chemother 66(10):2281–2283
Johnson JL et al (2006) Early and extended early bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis 10(6):605–612
Pletz MW et al (2004) Early bactericidal activity of moxifloxacin in treatment of pulmonary tuberculosis: a prospective, randomized study. Antimicrob Agents Chemother 48(3):780–782
Gillespie SH et al (2014) Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis. N Engl J Med 371(17):1577–1587
Jawahar MS et al (2013) Randomized clinical trial of thrice-weekly 4-month moxifloxacin or gatifloxacin containing regimens in the treatment of new sputum positive pulmonary tuberculosis patients. PLoS One 8(7):e67030
WHO. WHO Treatment Guidelines for Drug-Resistant Tuberculosis (2016 Update). 2016 January 1, 2018; Available from: http://apps.who.int/iris/bitstream/10665/250125/1/9789241549639-eng.pdf?ua=1
Gaude GS, Chaudhury A, Hattiholi J (2015) Drug-induced hepatitis and the risk factors for liver injury in pulmonary tuberculosis patients. J Family Med Prim Care 4(2):238–243
Abbara A et al (2017) Drug-induced liver injury from antituberculous treatment: a retrospective study from a large TB centre in the UK. BMC Infect Dis 17(1):231
Nader LA et al (2010) Hepatotoxicity due to rifampicin, isoniazid and pyrazinamide in patients with tuberculosis: is anti-HCV a risk factor? Ann Hepatol 9(1):70–74
Dossing M et al (1996) Liver injury during antituberculosis treatment: an 11-year study. Tuber Lung Dis 77(4):335–340
Lee AM et al (2002) Risk factors for hepatotoxicity associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection: experience from three public health tuberculosis clinics. Int J Tuberc Lung Dis 6(11):995–1000
Shakya R, Rao BS, Shrestha B (2004) Incidence of hepatotoxicity due to antitubercular medicines and assessment of risk factors. Ann Pharmacother 38(6):1074–1079
Crane M et al (2009) Immunopathogenesis of hepatic flare in HIV/hepatitis B virus (HBV)-coinfected individuals after the initiation of HBV-active antiretroviral therapy. J Infect Dis 199(7):974–981
Reis-Santos B et al (2015) Directly observed therapy of tuberculosis in Brazil: associated determinants and impact on treatment outcome. Int J Tuberc Lung Dis 19(10):1188–1193
Nguyen TA et al (2017) Video directly observed therapy to support adherence with treatment for tuberculosis in Vietnam: a prospective cohort study. Int J Infect Dis 65:85–89
Macaraig M et al (2017) A national survey on the use of electronic directly observed therapy for treatment of tuberculosis. J Public Health Manag Pract
Kaplan R et al (2016) An integrated community TB-HIV adherence model provides an alternative to DOT for tuberculosis patients in Cape Town. Int J Tuberc Lung Dis 20(9):1185–1191
Webb Mazinyo E et al (2016) Adherence to concurrent tuberculosis treatment and antiretroviral treatment among co-infected persons in South Africa, 2008–2010. PLoS One 11(7):e0159317
Hermans SM et al (2012) Integration of HIV and TB services results in improved TB treatment outcomes and earlier prioritized ART initiation in a large urban HIV clinic in Uganda. J Acquir Immune Defic Syndr 60(2):e29–e35
Egelund EF et al (2017) The pharmacological challenges of treating tuberculosis and HIV coinfections. Expert Rev Clin Pharmacol 10(2):213–223
Kaplan R et al (2014) Impact of ART on TB case fatality stratified by CD4 count for HIV-positive TB patients in Cape Town, South Africa (2009–2011). J Acquir Immune Defic Syndr 66(5):487–494
WHO. Consolidated guidelines on HIV prevention, diagnosis, treatment and care for key populations - 2016 update. 2016 December 10, 2017 January 1, 2018; Available from: http://www.who.int/hiv/pub/arv/arv-2016/en/
Havlir DV et al (2011) Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N Engl J Med 365(16):1482–1491
Abdool Karim SS et al (2010) Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med 362(8):697–706
Blanc FX et al (2011) Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. N Engl J Med 365(16):1471–1481
Mfinanga SG et al (2014) Early versus delayed initiation of highly active antiretroviral therapy for HIV-positive adults with newly diagnosed pulmonary tuberculosis (TB-HAART): a prospective, international, randomised, placebo-controlled trial. Lancet Infect Dis 14(7):563–571
Abdool Karim SS et al (2011) Integration of antiretroviral therapy with tuberculosis treatment. N Engl J Med 365(16):1492–1501
Uthman OA et al (2015) Optimal timing of antiretroviral therapy initiation for HIV-infected adults with newly diagnosed pulmonary tuberculosis: a systematic review and meta-analysis. Ann Intern Med 163(1):32–39
Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV. Department of Health and Human Services. 2017 December 10, 2017 January 1, 2018]; Available from: https://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-arv/27/tb-hiv
Torok ME et al (2011) Timing of initiation of antiretroviral therapy in human immunodeficiency virus (HIV)--associated tuberculous meningitis. Clin Infect Dis 52(11):1374–1383
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Pau, A.K., Kuriakose, S., Dooley, K.E., Maartens, G. (2019). Treatment of Drug-Sensitive Tuberculosis in Persons with HIV. In: Sereti, I., Bisson, G.P., Meintjes, G. (eds) HIV and Tuberculosis. Springer, Cham. https://doi.org/10.1007/978-3-030-29108-2_9
Download citation
DOI: https://doi.org/10.1007/978-3-030-29108-2_9
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-29107-5
Online ISBN: 978-3-030-29108-2
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)